it is not an ethics-free zone," he says.
The recommendations come less than a month after the China-UK Research Ethics (CURE) committee of the UK Medical Research Council (MRC) produced its own report on the subject, concluding that there is "comparatively little" inspection or review of compliance with research regulations in China. Qi Guoming, vice-chairman of the Chinese Medical Association and chairman of the medical ethics committee at the Chinese Ministry of Health, told the conference that the ministry was trying to come up with "more concrete regulations" for medical research, and that BIONET's recommendations could guide that process.
In May, for example, China toughened up its regulation of stemcell therapies (see Nature 459, 146-147; 2009). But there are still more than 100 institutions in China that continue to charge patients thousands of dollars for unproven stem-cell treatments, says Qiu Renzong, a bioethicist at the Chinese Academy of Social Sciences and co-chairman of the BIONET expert group.
BIONET's list of 30 recommendations includes establishing protocols to ensure that clinical trials of unproven therapies, such as stem-cell treatments, are not presented to patients as a cure. Research subjects should not be coerced into taking part in clinical trials, and all trial data should be published. BIONET also proposes that international ethical standards should be reflected by national regulation where possible, and that biobanks should ensure that any donors are fully informed about how their tissue will be used. The group adds that patients involved in clinical trials must have access to any beneficial therapies after the trials finish.
"Many of these recommendations reflect standards we would set for funding international collaboration," says Catherine Elliott, the MRC's head of clinical research support and ethics who coordinated the CURE report. "Some, however, would require much wider action and implementation than a single funder can provide." The new recommendations, she says, will trigger that wider discussion.
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Ethics scrutiny needed for Chinese-European projects "China is not the 'Wild East', it is not an ethics-free zone."
